Two-Drug HIV Treatment Regimens Effective in Latest Studies
March 8, 2017
In an interview on behalf of IFARA at CROI 2017, Fred Schaich spoke with Kimberly Smith about the potential for treating HIV with only two instead of three antiretrovirals. The goal here is to develop effective drugs with the fewest side effects.
The two SWORD studies presented at CROI randomized virally suppressed participants to continue their three- or four-drug treatment regimen or to switch to a new regimen consisting of dolutegravir (Tivicay, DTG) plus rilpivirine (Edurant). HIV levels remained undetectable in 95% of those in either study arm, proving that a two-drug regimen can be as effective as one with more medications.
Over 20% of enrollees in these trials were women and more than 25% were over 50 years old. Researchers wanted the study population to represent the demographic characteristics of those living with HIV, Smith noted.
Watch the video to learn more:
The video above has been posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.
Follow Barbara on Twitter: @reliabletran.
This article was provided by TheBodyPRO. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.